Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
Part of paid clinical trials in La Jolla, California.
- Sponsor
- University of California, San Diego
- Study ID
- NCT02103361
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ustekinumab — DRUG
- Guselkumab — DRUG
Study Details
The purpose of the OTIS Autoimmune Diseases in Pregnancy Study is to monitor planned and unplanned pregnancies exposed to certain medications, to evaluate the possible teratogenic effect of these medications and to follow live born infants for one year after birth. With respect to fetal outcome, it is important to evaluate the spectrum of outcomes that may be relevant to a medication exposure during pregnancy, and these include both easily recognizable defects which are visible at birth, as well as more subtle or delayed defects that may not be readily identifiable without special expertise and observation beyond the newborn period.
Key Dates
- Start date
- Nov 30, 2013
- Status verified
- Jan 2025
- Primary completion
- May 31, 2030
- Completion
- Feb 28, 2031
Study Design
- Enrollment
- 200 participants (estimated)
Arms
- Arm: Stelara (ustekinumab) exposedStelara (ustekinumab)-exposed pregnant women (this group is now closed to recruitment)
- Arm: Tremfya (guselkumab) exposedTremfya (guselkumab-exposed pregnant women
Primary Outcome Measure
Major structural malformations [ Time Frame: From 3 months prior to the first day of the last menstrual period and up to one year of age ]
Central Contacts
- Diana Johnson, MS877-311-8972
- Christina Chambers, PhD, MPH877-311-8972
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, San Diego | La Jolla | California | 92093 | Johnson Christina Chambers, PhD, MPH (PRINCIPAL_INVESTIGATOR) |
Find similar trials in La Jolla, CA
Related Studies
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque PsoriasisPHASE4 · Recruiting · Bausch Health Americas, Inc. · Fountain Valley, California
- Stem Cell Transplantation in Crohn's DiseasePHASE1/PHASE2 · Recruiting · Cedars-Sinai Medical Center · Los Angeles, California
- UCLA Perinatal Biospecimen RepositoryRecruiting · Yalda Afshar, MD, PhD · Los Angeles, California